Neurofibromatosis Type 1 | CHOP Research Institute

Neurofibromatosis Type 1

Published on
Oct 27, 2021
A rare disease hack-a-thon leads to an unusual collaboration between D3b’s bioinformaticians, including Adam Resnick, PhD, and American Airlines’ software engineers.
Published on
Feb 26, 2021
Data from a phase-2 study show that cabozantinib effectively treats plexiform neurofibromas in patients with neurofibromatosis type 1.

Dr. Shah's clinical research interests are focused in the areas of neurofibromatosis type 1 and retinoblastoma. These studies range from translational studies to clinical trials of novel therapeutics to international consortiums studying long-term effects of therapy.

shahac [at]